These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30280939)

  • 1. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.
    Kaur A; Kannan D; Mehta SK; Singh S; Salunke DB
    Expert Opin Ther Pat; 2018 Nov; 28(11):837-847. PubMed ID: 30280939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of toll-like receptor agonists as an adjuvant component to malaria blood-stage vaccine].
    Xie CB; Qian F; Xu HJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2011 Oct; 29(5):389-93. PubMed ID: 24830205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses.
    Vasou A; Sultanoglu N; Goodbourn S; Randall RE; Kostrikis LG
    Viruses; 2017 Jul; 9(7):. PubMed ID: 28703784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
    Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
    Front Immunol; 2018; 9():2874. PubMed ID: 30619259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.
    Ong GH; Lian BSX; Kawasaki T; Kawai T
    Front Cell Infect Microbiol; 2021; 11():745016. PubMed ID: 34692565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.
    Maisonneuve C; Bertholet S; Philpott DJ; De Gregorio E
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12294-9. PubMed ID: 25136133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR based therapeutics.
    Dunne A; Marshall NA; Mills KH
    Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
    Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
    Front Immunol; 2020; 11():599083. PubMed ID: 33281825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Properties of Potential Synthetic Vaccine Adjuvants - TLR Agonists.
    Honegr J; Soukup O; Doležal R; Malinak D; Penhaker M; Prymula R; Kuca K
    Curr Med Chem; 2015; 22(29):3306-25. PubMed ID: 26295466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.
    Mata E; Salvador A; Igartua M; Hernández RM; Pedraz JL
    Biomed Res Int; 2013; 2013():282913. PubMed ID: 23710439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flagellin as a vaccine adjuvant.
    Cui B; Liu X; Fang Y; Zhou P; Zhang Y; Wang Y
    Expert Rev Vaccines; 2018 Apr; 17(4):335-349. PubMed ID: 29580106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulatory properties of Toll-like receptor ligands in chickens.
    St Paul M; Brisbin JT; Abdul-Careem MF; Sharif S
    Vet Immunol Immunopathol; 2013 Apr; 152(3-4):191-9. PubMed ID: 23305711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
    Kumar S; Sunagar R; Gosselin E
    Front Immunol; 2019; 10():1144. PubMed ID: 31191528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor agonists: a patent review (2011 - 2013).
    Hussein WM; Liu TY; Skwarczynski M; Toth I
    Expert Opin Ther Pat; 2014 Apr; 24(4):453-70. PubMed ID: 24456079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor agonists as cancer vaccine adjuvants.
    Jeon D; Hill E; McNeel DG
    Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines.
    Fujita Y; Taguchi H
    Ther Deliv; 2012 Jun; 3(6):749-60. PubMed ID: 22838070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants.
    Olive C
    Expert Rev Vaccines; 2012 Feb; 11(2):237-56. PubMed ID: 22309671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.
    Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Dolzhikova IV; Stanhope-Baker P; Naroditsky BS; Gudkov AV; Logunov DY; Gintsburg AL
    PLoS One; 2016; 11(5):e0155650. PubMed ID: 27187797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.